UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells

References

• Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, Richter C, Zips D, Bortfeld T. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016 Apr;16(4):234–12. Epub 2016 Mar 18. doi:10.1038/nrc.2016.18.
   PubMed Web of Science ®Google Scholar
• Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer stem cells and radioresistance: DNA repair and beyond. Cancers (Basel). 2019 Jun 21;11(6):E862. doi:10.3390/cancers11060862.
   PubMed Web of Science ®Google Scholar
• Maier P, Hartmann L, Wenz F, Herskind C. Cellular pathways in response to ionizing radiation and their targetability for tumor radiosensitization. Int J Mol Sci. 2016 Jan 14;17(1):E102. doi:10.3390/ijms17010102.
   PubMed Web of Science ®Google Scholar
• Kurth I, Hein L, Mäbert K, Peitzsch C, Koi L, Cojoc M, Kunz-Schughart L, Baumann M, Dubrovska A. Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. Oncotarget. 2015 Oct 27;6(33):34494–34509. doi:10.18632/oncotarget.5417.
   PubMedGoogle Scholar
• Zeman EM. 2012. Biologic basis of radiation oncology, in clinical radiation oncology. 3ed.UK: Saunders Elsevier.
   Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018 Jul 5;379(1):64–73. doi:10.1056/NEJMra1706169.
   PubMed Web of Science ®Google Scholar
• Bouchkouj N, Kasamon YL, de Claro RA, George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE, Pazdur R. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin Cancer Res. 2019 Mar 15;25(6):1702–1708. Epub 2018 Nov 9. doi:10.1158/1078-0432.CCR-18-2743.
   PubMed Web of Science ®Google Scholar
• Freyer CW. Tisagenlecleucel: the first CAR on the highway to remission for acute lymphoblastic leukemia. J Adv Pract Oncol. 2018 Jul-Aug;9(5):537–544. Epub 2018 Jul 1.
   PubMedGoogle Scholar
• Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016 May;30(3):157–167. Epub 2015 Nov 6. doi:10.1016/j.blre.2015.10.003.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol. 2010;2010:956304. Epub 2010 May 5. doi:10.1155/2010/956304.
   PubMed Web of Science ®Google Scholar
• Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018 Jun;23(6):1175–1182. Epub 2018 Mar 1. doi:10.1016/j.drudis.2018.02.012.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018 Jan;15(1):47–62. Epub 2017 Sep 19. doi:10.1038/nrclinonc.2017.148.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ Jr. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012 Apr 1;72(7):1844–1852. Epub 2012 Feb 7. doi:10.1158/0008-5472.CAN-11-3890.
   PubMed Web of Science ®Google Scholar
• Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015 Mar 4;137(8):2832–2835. Epub 2015 Feb 24. doi:10.1021/jacs.5b00106.
   PubMed Web of Science ®Google Scholar
• Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459–68. Epub 2016 Jan 12. doi:10.1073/pnas.1524155113.
   PubMed Web of Science ®Google Scholar
• Bachmann M. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells. Immunology Letters. 2019 May;211:13–22. doi:10.1016/j.imlet.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Arndt C, Bachmann M, Bergmann R, Berndt N, Feldmann A, Koristka S. Theranostic CAR T cell targeting: A brief review. J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533–540. Epub 2019 Jun 6. doi:10.1002/jlcr.3727.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Arndt C, Koristka S, Berndt N, Bergmann R, Bachmann M. Conventional CARs versus modular CARs. Cancer Immunol Immunother. 2019 Oct;68(10):1713–1719. Epub 2019 Sep 21. Review. PMID: 31542798. doi:10.1007/s00262-019-02399-5.
   PubMed Web of Science ®Google Scholar
• Koristka S, Cartellieri M, Feldmann A, Arndt C, Loff S, Michalk I, Aliperta R, von Bonin M, Bornhäuser M, Ehninger A, et al. Flexible antigen-specific redirection of human regulatory T cells via a novel universal chimeric antigen receptor system. Blood. 2014;124(21):3494. doi:10.1182/blood.V124.21.3494.3494.
   Web of Science ®Google Scholar
• Cartellieri M, Loff S, von Bonin M, Bejestani EP, Ehninger A, Feldmann A, Koristka S, Arndt C, Ehninger G, Bachmann M. Unicar: A novel modular retargeting platform technology for CAR T cells. Blood. 2015;126(23):5549. doi:10.1182/blood.V126.23.5549.5549.
   Web of Science ®Google Scholar
• Arndt C, Feldmann A, Koristka S, Schäfer M, Bergmann R, Mitwasi N, Berndt N, Bachmann D, Kegler A, Schmitz M, et al. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. Oncoimmunology. 2019 Sep 7;8(11):1659095. eCollection 2019. PMID: 31646084. doi:10.1080/2162402X.2019.1659095.
   PubMed Web of Science ®Google Scholar
• Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A, Gärtner S, et al. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology. 2017 Feb 6;6(4):e1287246. eCollection 2017. doi:10.1080/2162402X.2017.1287246.
   PubMed Web of Science ®Google Scholar
• Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, Schmitz M, Pietzsch J, Steinbach J, Bachmann M. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018 May 22;9(39):25597–25616. eCollection 2018 May 22. doi:10.18632/oncotarget.25390.
   PubMedGoogle Scholar
• Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016 Aug 12;6(8):e458. doi:10.1038/bcj.2016.61.
   PubMed Web of Science ®Google Scholar
• Bachmann D, Aliperta R, Bergmann R, Feldmann A, Koristka S, Arndt C, Loff S, Welzel P, Albert S, Kegler A, et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget. 2017 Dec 21;9(7):7487–7500. eCollection 2018 Jan 26. doi:10.18632/oncotarget.23556.
   PubMedGoogle Scholar
• Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, Pietzsch J, Novo C, Videira P, Bachmann M. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018 Aug 22;8(9):81. doi:10.1038/s41408-018-0113-4.
   PubMed Web of Science ®Google Scholar
• Jureczek J, Bergmann R, Berndt N, Koristka S, Kegler A, Puentes-Cala E, Soto JA, Arndt C, Bachmann M, Feldmann A. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells. Sci Rep. 2019 Jul 22;9(1):10547. doi:10.1038/s41598-019-47044-4.
   PubMed Web of Science ®Google Scholar
• Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013 May;42:105–116. Epub 2013 Jan 22. doi:10.1016/j.jaut.2013.01.002.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34–74. Epub 2013 Nov 20. doi:10.1016/j.phrs.2013.11.002..
   PubMed Web of Science ®Google Scholar
• Cantor JM, Ginsberg MH. CD98 at the crossroads of adaptive immunity and cancer. J Cell Sci. 2012 Mar 15;125(Pt 6):1373–1382. Epub 2012 Apr 12. doi:10.1242/jcs.096040.
   PubMed Web of Science ®Google Scholar
• Napolitano L, Scalise M, Galluccio M, Pochini L, Albanese LM, Indiveri C. LAT1 is the transport competent unit of the LAT1/CD98 heterodimeric amino acid transporter. Int J Biochem Cell Biol. 2015 Oct;67:25–33. Epub 2015 Aug 6. doi:10.1016/j.biocel.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Rosell A, Meury M, Álvarez-Marimon E, Costa M, Pérez-Cano L, Zorzano A, Fernández-Recio J, Palacín M, Fotiadis D. Structural bases for the interaction and stabilization of the human amino acid transporter LAT2 with its ancillary protein 4F2hc. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):2966–2971. Epub 2014 Feb 10. doi:10.1073/pnas.1323779111.
   PubMed Web of Science ®Google Scholar
• Digomann D, Kurth I, Tyutyunnykova A, Chen O, Löck S, Gorodetska I, Peitzsch C, Skvortsova II, Negro G, Aschenbrenner B, et al. The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity. Clin Cancer Res. 2019 May 15;25(10):3152–3163. Epub 2019 Jan 22. doi:10.1158/1078-0432.CCR-18-2951.
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90(11):824–832. doi:10.1093/jnci/90.11.824.
   PubMed Web of Science ®Google Scholar
• Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58(3):959–965. doi:10.1016/j.ijrobp.2003.07.010.
   PubMed Web of Science ®Google Scholar
• Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58(2):561–566. doi:10.1016/j.ijrobp.2003.09.043.
   PubMed Web of Science ®Google Scholar
• Ang KK, Berkey BA, Tu X, Zhang H-Z, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356.
   PubMed Web of Science ®Google Scholar
• Martens-de Kemp SR, Brink A, Stigter-van Walsum M, Damen JM, Rustenburg F, Wu T, van Wieringen WN, Schuurhuis GJ, Braakhuis BJ, Slijper M, et al. CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell properties. Stem Cell Res. 2013 May;10(3):477–488. Epub 2013 Feb 18. doi:10.1016/j.scr.2013.02.004.
   PubMed Web of Science ®Google Scholar
• Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003;57(1):246–254. doi:10.1016/S0360-3016(03)00511-X.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys. 1994;29(2):243–247. doi:10.1016/0360-3016(94)90269-0.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, Schmitz M, Temme A, Cartellieri M, Bachmann M. Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate. 2011 Jun 15;71(9):998–1011. Epub 2010 Dec 28. doi:10.1002/pros.21315.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, Cartellieri M, Koristka S, Michalk I, Lindemann D, Schmitz M, et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol. 2012 Sep 15;189(6):3249–3259. Epub 2012 Aug 8. doi:10.4049/jimmunol.1200341.
   PubMed Web of Science ®Google Scholar
• Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H, Bippes CC, Wehner R, Schmitz M, von Bonin M, et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol. 2011 Dec;49(3):474–482. Epub 2011 Oct 19. doi:10.1016/j.molimm.2011.09.019.
   PubMed Web of Science ®Google Scholar
• Arndt C, Koristka S, Feldmann A, Bergmann R, Bachmann M. Coomassie brilliant blue staining of polyacrylamide gels. Methods Mol Biol. 2018;1853:27–30. doi:10.1007/978-1-4939-8745-0_4.
   PubMedGoogle Scholar
• Arndt C, Feldmann A, Töpfer K, Koristka S, Cartellieri M, Temme A, Ehninger A, Ehninger G, Bachmann M. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells. Prostate. 2014 Sep;74(13):1347–1358. Epub 2014 Jul 22. doi:10.1002/pros.22851.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, Töpfer K, Krüger T, Geib M, Michalk I, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014 Apr 3;9(4):e93745. eCollection 2014. doi:10.1371/journal.pone.0093745.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, Aliperta R, Hetzenecker M, Ludwig F, Albert S, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”. Oncotarget. 2017 May 9;8(19):31368–31385. doi:10.18632/oncotarget.15572.
   PubMedGoogle Scholar
• Mitwasi N, Feldmann A, Bergmann R, Berndt N, Arndt C, Koristka S, Kegler A, Jureczek J, Hoffmann A, Ehninger A, et al. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells. Oncotarget. 2017 Sep 18;8(65):108584–108603. eCollection 2017 Dec 12. doi:10.18632/oncotarget.21017.
   PubMedGoogle Scholar
• Koristka S, Kegler A, Bergmann R, Arndt C, Feldmann A, Albert S, Cartellieri M, Ehninger A, Ehninger G, Middeke JM, et al. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. J Autoimmun. 2018 Jun;90:116–131. Epub 2018 Mar 2. doi:10.1016/j.jaut.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Koristka S, Ziller-Walter P, Bergmann R, Arndt C, Feldmann A, Kegler A, Cartellieri M, Ehninger A, Ehninger G, Bornhäuser M, et al. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells. Cancer Immunol Immunother. 2019 Aug 14;68(9):1401–1415. Epub ahead of print. doi:10.1007/s00262-019-02376-y.
   PubMed Web of Science ®Google Scholar
• Fasslrinner F, Arndt C, Koristka S, Feldmann A, Altmann H, von Bonin M, Schmitz M, Bornhäuser M, Bachmann M. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia. Br J Haematol. 2019 Sep;186(5):735–740. Epub 2019 May 23. doi:10.1111/bjh.15975.
   PubMed Web of Science ®Google Scholar
• Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, Koristka S, Michalk I, Stamova S, Berndt N, Gocht A, et al. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia. 2014 Jan;28(1):59–69. Epub 2013 Aug 20. doi:10.1038/leu.2013.243.
   PubMed Web of Science ®Google Scholar
• Minn I, Rowe SP, Pomper MG. Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. Lancet Oncol. 2019 Aug;20(8):e443–e451. Epub 2019 Jul 29. doi:10.1016/S1470-2045(19)30461-9.
   PubMed Web of Science ®Google Scholar
• DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar VK, Sadelain M. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther. 2018 Nov 7;26(11):2542–2552. Epub 2018 Sep 13. doi:10.1016/j.ymthe.2018.09.008.
   PubMed Web of Science ®Google Scholar
• Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018 Feb 15;78(4):1031–1043. Epub 2017 Dec 8. doi:10.1158/0008-5472.CAN-17-1788.
   PubMed Web of Science ®Google Scholar
• Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017 Aug 18;9:363–371. eCollection 2017. doi:10.2147/CMAR.S115761.
   PubMed Web of Science ®Google Scholar
• Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2014 Jun;73(6):1227–1239. Epub 2014 Apr 9. doi:10.1007/s00280-014-2459-z.
   PubMed Web of Science ®Google Scholar
• Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Role of immunotherapy in head and neck cancer. Semin Radiat Oncol. 2018 Jan;28(1):12–16. doi:10.1016/j.semradonc.2017.08.009.
   PubMed Web of Science ®Google Scholar
• Hwang WY1, Foote J. Immunogenicity of engineered antibodies. Methods. 2005 May;36(1):3–10. doi:10.1016/j.ymeth.2005.01.001.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS, Thomas CA, Strominger JL, Fauci AS. Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol. 1981 Apr;126(4):1409–1414.
   PubMed Web of Science ®Google Scholar
• Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014 Jan 16;123(3):356–365. Epub 2013 Dec 3. doi:10.1182/blood-2013-08-523548.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006 Feb 9;354(6):567–578. doi:10.1056/NEJMoa053422.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21–28. Epub 2009 Nov 10. doi:10.1016/S1470-2045(09)70311-0.
   PubMed Web of Science ®Google Scholar
• Flynn JP, O’Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res. 2017 Apr;6(2):159–168. doi:10.21037/tlcr.2017.03.07.
   PubMed Web of Science ®Google Scholar
• Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM, Zips D. Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation. Clin Transl Radiat Oncol. 2017 Feb 4;2:29–35. eCollection 2017 Feb. doi:10.1016/j.ctro.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Xiaoqing L, Weihong C. Mechanisms of failure of chimeric antigen receptor T-cell therapy. Curr Opin Hematol. 2019 Nov;26(6):427–433. doi:10.1097/MOH.0000000000000548.
   PubMed Web of Science ®Google Scholar
• Timmers M, Roex G, Wang Y, Campillo-Davo D, Van Tendeloo VFI, Chu Y, Berneman ZN, Luo F, Van Acker HH, Anguille S. Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen. Front Immunol. 2019 Jul 16;10:1613. eCollection 2019. doi:10.3389/fimmu.2019.01613.
   PubMed Web of Science ®Google Scholar